Efzofitimod 3 mg/kg + Efzofitimod 5 mg/kg + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Sarcoidosis
Conditions
Pulmonary Sarcoidosis
Trial Timeline
Sep 15, 2022 → Aug 31, 2025
NCT ID
NCT05415137About Efzofitimod 3 mg/kg + Efzofitimod 5 mg/kg + Placebo
Efzofitimod 3 mg/kg + Efzofitimod 5 mg/kg + Placebo is a phase 3 stage product being developed by KYORIN Pharmaceutical for Pulmonary Sarcoidosis. The current trial status is active. This product is registered under clinical trial identifier NCT05415137. Target conditions include Pulmonary Sarcoidosis.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Sarcoidosis were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05415137 | Phase 3 | Active |
Competing Products
20 competing products in Pulmonary Sarcoidosis